PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.222
https://www.valueinhealthjournal.com/article/S1098-3015(18)33522-8/fulltext
Title :
PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33522-8&doi=10.1016/j.jval.2018.09.222
First page :
Section Title :
Open access? :
No
Section Order :
1611